UroGen Pharma Ltd
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +344.8% | +18.9% | +227.7% | +37.1% | +95.4% | -39.7% | -1.9% | +13.3% | +31.5% | +60.2% | -29.8% | |
| – | +346.2% | +15.2% | +237.9% | +37.3% | +45.4% | -22.2% | -1.1% | +12.7% | +31.2% | +63.2% | -32.6% | |
| – | +364.5% | +18.8% | +73.2% | +173.8% | -51.0% | +6.4% | -16.1% | +24.9% | +71.5% | +81.0% | -35.6% | |
| – | +364.5% | +18.8% | +241.7% | +38.8% | +45.2% | -30.6% | -12.6% | +12.1% | +37.0% | +72.8% | -49.1% | |
| – | – | – | +138.6% | – | – | – | +66.3% | +8.4% | +21.6% | +31.5% | +62.9% | |
| – | – | – | +201.0% | – | – | – | +146.0% | -10.5% | +31.2% | +62.6% | +78.4% | |
| – | +264.8% | +186.1% | +8.6% | +17.8% | +397.0% | -10.8% | -53.2% | -34.1% | – | – | – | |
| – | +151.1% | +201.7% | +4.2% | +91.4% | +64.0% | +16.1% | +334.0% | +102.1% | +8.2% | +20.9% | +3.9% | |
| – | +151.1% | +40.2% | +124.3% | +91.4% | +44.7% | +10.0% | +4.4% | +6.9% | +30.5% | +47.2% | +1.0% | |
| – | – | – | – | – | – | – | +79.1% | -71.7% | -13.0% | +86.8% | – | |
| – | +234.5% | +9.6% | +51.0% | +50.5% | +9.9% | -30.3% | +76.9% | -4.5% | +17.9% | +67.8% | +11.0% | |
| – | – | +314.2% | – | – | – | – | – | – | +1.0% | +23.5% | +0.4% | |
| – | +394.6% | -4.9% | +320.2% | +31.5% | +100.1% | -46.6% | -91.3% | -1,162.2% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.1% | +419.9% | -18.8% | +62.1% | +30.3% | +6.1% | +2.6% | +2.1% | +26.4% | +48.7% | +12.2% |
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.